high5immunology.tv | Rheumatology | EULAR 2026
Spotlight Discussions Axial Spondyloarthritis - ENG
ENG
EULAR 2026
Nanobodies - the beginning of a new era?
Spotlight Discussions Psoriatic arthritis - ENG
ENG
AFFINITY
EULAR 2026
Which patients benefit most from dual targeted…
ENG
BE BOLD
EULAR 2026
H2H bimekizumab vs. risankizumab - long awaited, and…
ENG
TOGETHER-PSA,DIPSA, RISE
EULAR 2026
IL-17 Inhibitor plus GLP-1 receptor agonist: the start…
Spotlight Discussion Rheumatoid Arthritis - ENG
ENG
COMPARE
EULAR 2026
The future of lymphocyte depletion therapies
ENG
ANCHOR-RA
EULAR 2026
Risk factors for ILD: long awaited data but what are…
ENG
RA-BRIDGE, RA-BRANCH
EULAR 2026
JAKi safety - the profiling of the patient is…
ENG
EULAR 2026
Cancer risk in RA: stick to biologics or stop them?
Spotlight Discussions Vasculitis - ENG
ENG
JAK-SPARE, REPLENISH
EULAR 2026
Eliminating corticosteroids in PMR: wishful thinking or…
Spotlight Discussions Axial Spondyloarthritis - ENG
ENG
EULAR 2026
Nanobodies - the beginning of a new era?
axSpA 100 sec - ENG
ENG
AxSpA INCEPTION
EULAR 2026
ASAS-SPARTAN revised classification criteria 2026
ENG
EULAR 2026
Do safety differences between TNF inhibitors, IL-17…
ENG
ROC-SpA
EULAR 2026
Comparable efficacy of TNFi and IL-17i as second-line…
ENG
OLINGUITO
EULAR 2026
Filgotinib is also effective in axSpA!
ENG
SPARTACUS
EULAR 2026
Do we need conventional therapy for axSpA?
ENG
IMPROVE-AXSPA
EULAR 2026
Clinical evaluation outweighs imaging in axSpA!
ENG
EULAR 2026
Sonelokimab: An IL-17A/F-Inhibiting Nanobody in axSpA
axSpA 100 sec - multi language
GER
AxSpA INCEPTION
EULAR 2026
Revidierte ASAS-SPARTAN Klassifikationskriterien 2026
GER
SPARTACUS
EULAR 2026
Brauchen wir konventionelle Therapie bei axSpA?
GER
EULAR 2026
Sonelokimab: Ein IL-17A/F-hemmendes Nanobody bei axSpA
GER
IMPROVE-AXSPA
EULAR 2026
Klinik führt vor Bildgebung bei axSpA!
GER
EULAR 2026
Doch Sicherheitsunterschiede zwischen TNFi, IL-17i und…
GER
OLINGUITO
EULAR 2026
Filgotinib wirkt auch bei der axSpA!
GER
ROC-SpA
EULAR 2026
Gleiche Wirkung von TNFi und IL-17i als…
Spotlight Discussions Psoriatic arthritis - ENG
ENG
AFFINITY
EULAR 2026
Which patients benefit most from dual targeted…
ENG
TOGETHER-PSA,DIPSA, RISE
EULAR 2026
IL-17 Inhibitor plus GLP-1 receptor agonist: the start…
ENG
BE BOLD
EULAR 2026
H2H bimekizumab vs. risankizumab - long awaited, and…
PsA 100 sec - ENG
ENG
BE BOLD
EULAR 2026
H2H bimekizumab vs. risankizumab: the early bird…
ENG
EULAR 2026
Difference in the definition of treatment refractory…
ENG
EULAR 2026
Two years, but then! Cardiovascular risk of JAKis vs…
ENG
EULAR 2026
Impact of biologic therapies and targeted synthetic…
ENG
AFFINITY
EULAR 2026
Impact of guselkumab and golimumab combination therapy…
ENG
TOGETHER-PSA
EULAR 2026
IL-17 Inhibitor plus GLP-1 receptor agonist: the start…
ENG
EULAR 2026
Treatment with glucagon-like peptide-1 receptor…
ENG
EULAR 2026
Probiotics in patients with PsA: do they have an…
ENG
TOGETHER-PSA
EULAR 2026
Obesity & PsA - a novel approach
ENG
EULAR 2026
Still a challenge - impact of diet on body weight in…
ENG
TOGETHER-PSA
EULAR 2026
Parallel treatment or synergy? Ixekizumab and…
ENG
Be BOLD
EULAR 2026
H2H bimekizumab vs. risankizumab
ENG
PsABIOnd
EULAR 2026
Defintion of treatment persistence refractory PsA…
PsA 100 sec - multi language
GER
EULAR 2026
2 Jahre, aber dann! Kardiovaskuläres Risiko JAKi vs.…
GER
EULAR 2026
Auswirkung einer Diät auf das Körpergewicht bei…
GER
AFFINITY
EULAR 2026
Effekt der Kombination von Guselukumab & Golimumab im…
GER
TOGETHER-PSA
EULAR 2026
Parallel behandelt oder Synergismus? Ixekizumab und…
ITA
PsABIOnd
EULAR 2026
Definizione della persistenza al trattamento nei…
GER
EULAR 2026
Probiotika bei PsA Patienten - haben sie einen Effekt?
GER
BE BOLD
EULAR 2026
H2H Bimekizumab vs. Risankizumab: der frühe Vogel fängt…
GER
Be BOLD
EULAR 2026
H2H Bimekizumab vs. Risankizumab
GER
TOGETHER-PSA
EULAR 2026
Kombination aus IL-17-Inhibitor und…
ITA
EULAR 2026
Il trattamento con agonisti del recettore del…
ITA
EULAR 2026
Impatto delle terapie biologiche e dei DMARD sintetici…
ITA
EULAR 2026
Differenze nella definizione della refrattarietà al…
Spotlight Discussion Rheumatoid Arthritis - ENG
ENG
EULAR 2026
Cancer risk in RA: stick to biologics or stop them?
ENG
RA-BRIDGE, RA-BRANCH
EULAR 2026
JAKi safety - the profiling of the patient is…
ENG
ANCHOR-RA
EULAR 2026
Risk factors for ILD: long awaited data but what are…
ENG
COMPARE
EULAR 2026
The future of lymphocyte depletion therapies
RA 100 sec - ENG
ENG
EULAR 2026
Can difficult-to-treat RA be a true biological…
ENG
EULAR 2026
T cell depletion in RA
ENG
COMPARE
EULAR 2026
B cell depletion in RA
ENG
RA-BRIDGE, RA-BRANCHE
EULAR 2026
JAKi safety: drug-specific or class-wide?
ENG
EULAR 2026
EULAR panoramic view on RA
ENG
SUNSTAR
EULAR 2026
H2H comparison of monoclonal antibodies in RA
ENG
ANCHOR-RA
EULAR 2026
High-resolution CT should be considered in RA patients…
ENG
JAK-POT
EULAR 2026
Cancer risk with JAKi compared to bDMARDs in RA –…
ENG
COMPARE
EULAR 2026
CAR T Cells in Rheumatoid Arthritis: Towards an Immune…
ENG
RA-BRIDGE, RA-BRANCH
EULAR 2026
Safety of Baricitinib regarding VTE
RA 100 sec - multi language
POR
ANCHOR-RA
EULAR 2026
A TC de alta resolução deve ser considerada nos doentes…
ESP
RA-BRIDGE, RA-BRANCH
EULAR 2026
Seguridad de baricitinib para eventos tromboembólicos
POR
EULAR 2026
Visão panorâmica da artrite reumatoide no EULAR
FRA
COMPARE
EULAR 2026
Les CAR T anti-CD19 ouvrent une nouvelle voie dans la…
POR
EULAR 2026
A artrite reumatoide difícil de tratar pode…
GER
RA-BRIDGE, RA-BRANCHE
EULAR 2026
JAKi Safety: Substanz vs. JAKi-Klasse?
NOR
JAK-POT
EULAR 2026
Kreftrisiko ved behandling med JAK-hemmere sammenliknet…
Gout 100 sec - ENG
ENG
NOR-GOUT
EULAR 2026
Association btw crystal depositions and erosions in the…
ENG
EULAR 2026
Stopping or Continuing ULT in Gout?
ENG
EULAR 2026
Febuxostat extended-release formulation for treating…
Gout 100 sec - multi language
ESP
EULAR 2026
Febuxostat de liberación retardada para gota
NOR
NOR-GOUT
EULAR 2026
Assosiasjon mellom krystallavleiringer og erosjoner i…
FRA
EULAR 2026
Faut-il poursuivre le traitement hypo-uricémiant…
Sjogren's disease 100 sec - ENG
ENG
ANISE-II
EULAR 2026
Promising Results with Anifrolumab in Sjögren’s Disease
ENG
EULAR 2026
A novel therapy for Sjögren's disease
Sjogren's disease 100 sec - multi language
FRA
ANISE-II
EULAR 2026
L’anifrolumab, une nouvelle piste thérapeutique dans la…
Systemic lupus erythematosus 100 sec - ENG
ENG
JASMINE-SLE
EULAR 2026
Is antibody recycling a promising therapeutic strategy?
Systemic lupus erythematosus 100 sec - multi language
GER
JASMINE-SLE
EULAR 2026
Ist das Recycling von Antikörpern ein…
Spotlight Discussions Vasculitis - ENG
ENG
JAK-SPARE, REPLENISH
EULAR 2026
Eliminating corticosteroids in PMR: wishful thinking or…
Vasculitis 100 sec - ENG
ENG
SELECT-GCA
EULAR 2026
Upadacitinib in the managment of GCA
ENG
REPLENISH
EULAR 2026
PMR and secukinumab
ENG
JAK-SPARE
EULAR 2026
Baricitinib for early PMR
ENG
REPLENISH
EULAR 2026
Things are moving forward at PMR!
Vasculitis 100 sec - multi language
ESP
JAK-SPARE
EULAR 2026
Baricitinib para PMR de reciente diagóstico
GER
REPLENISH
EULAR 2026
Bei PMR tut sich was!
Cross-cutting highlights 100 sec - ENG
ENG
ICONIC-LEAD, ICONIC-ADVANCE 1, ICONIC-ADVANCE 2
EULAR 2026
Innovative oral IL-23 therapy for plaque psoriasis
ENG
EULAR 2026
Vexas
ENG
EULAR 2026
Microenvironmental hypoxia and HIF-1α activity…
ENG
EULAR 2026
New medication approved for IgG4
ENG
EULAR 2026
Management of necrotizing myopathy
ENG
DANBIO
EULAR 2026
Switching between biosimilars is safe!
Cross-cutting highlights 100 sec - multi language
NOR
DANBIO
EULAR 2026
Bytte mellom biotilsvarende er trygt!
ITA
EULAR 2026
L’ipossia microambientale e l’attività di HIF-1α si…
